Good response of an aggressive rare variant of signet ring cell carcinoma of prostate with hormonal therapy

BMJ Case Rep. 2017 Mar 8:2017:bcr2016217567. doi: 10.1136/bcr-2016-217567.

Abstract

Primary signet ring cell carcinoma (SRCC) of the prostate is a rare entity, characterised by its aggressive nature and dismal prognosis. We report a case of an advanced SRCC of the prostate presenting as a large pelvic mass with obstructive uropathy and rectal involvement managed by complete androgen blockade. At 24 months follow-up, the patient has no evidence of progression or metastasis. Aggressive management with multimodality approach combining surgery, radiation and hormonal ablation can result in long disease-free survival in some patients, despite the aggressive nature of this disease.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use*
  • Carcinoma, Signet Ring Cell / drug therapy*
  • Carcinoma, Signet Ring Cell / surgery
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / surgery
  • Treatment Outcome

Substances

  • Androgen Antagonists